InsiderSignal.AI

InsiderSignal.ai

AKTS - Aktis Oncology, Inc.

Insider Purchase by Foley Todd (Dir, 10%)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

2 months ago, Foley Todd, serving as Dir, 10% owner at Aktis Oncology, Inc. (AKTS), purchased 232,870 shares at $18.00 per share, for a total transaction value of $4,191,660.00. Following this transaction, Foley Todd now holds 4,235,403 shares of AKTS.

This purchase represents a 6.00% increase in Foley Todd's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, January 12, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, January 14, 2026, 2 days after the trade was made.

Aktis Oncology, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Foley Todd

Dir, 10%

Todd Foley is a Co-Founder and Chairman of the Board at Aktis Oncology, Inc. (NASDAQ: AKTS), a biotechnology company focused on developing targeted alpha radiopharmaceuticals for cancer treatment.[[1]](https://www.aktisoncology.com/team/todd-foley/)[[2]](https://www.marketscreener.com/insider/TODD-FOLEY-A04DHH/)[[6]](https://www.aktisoncology.com/our-team/) As a seasoned biotech investor, he serves as Managing Director at MPM BioImpact (formerly MPM Capital), where he has been since 1999, and chairs boards of several portfolio companies including ashibio and Crossbow Therapeutics, while also directing others like Repare Therapeutics and Tetherex Pharmaceuticals.[[1]](https://www.aktisoncology.com/team/todd-foley/)[[3]](https://targetcancer.org/team-member/todd-foley/)[[4]](https://mpmbioimpact.com/team/todd-foley-m-b-a/) Foley's career highlights include guiding Selexys Pharmaceuticals to a $665 million acquisition by Novartis in 2016 and serving on the board of Semma Therapeutics, acquired by Vertex for $950 million in 2019.[[1]](https://www.aktisoncology.com/team/todd-foley/)[[4]](https://mpmbioimpact.com/team/todd-foley-m-b-a/) Earlier, he worked in business development at Genentech and management consulting at Arthur D. Little. He holds an MBA from Harvard Business School and a BS in Chemistry from MIT.[[1]](https://www.aktisoncology.com/team/todd-foley/)[[3]](https://targetcancer.org/team-member/todd-foley/) Recently, as a director, Foley purchased 232,870 shares of AKTS at $18 per share for $4.19 million and acquired additional shares via preferred stock conversion.[[5]](https://www.investing.com/news/insider-trading-news/aktis-oncology-director-foley-buys-419-million-in-shares-93CH-4448480)

View full insider profile →

Trade Price

$18.00

Quantity

232,870

Total Value

$4,191,660.00

Shares Owned

4,235,403

Trade Date

Monday, January 12, 2026

85 days ago

SEC Filing Date

Wednesday, January 14, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Aktis Oncology, Inc.

Company Overview

No company information available
View news mentioning AKTS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/3106799

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime